Tapinarof cream 1% in plaque psoriasis: a profile of its use

<p>  </p> <p><strong>Declarations</strong></p> <p><strong>Funding</strong> The preparation of this review was not supported by any external funding.</p> <p><strong>Authorship and conflict of interest</strong> M. Shirley is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</p> <p><strong>Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability</strong> Not applicable.</p> <p><br></p> <p>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews" target="_blank"><strong>here</strong></a>.</p> <p><br></p> <p>Abstract</p> <p> Tapinarof (VTAMA^®) cream 1%, a topical, non-steroidal, aryl hydrocarbon receptor agonist, presents a valuable addition to the therapy options for topical treatment of plaque psoriasis in adults. In the pivotal 12-week, randomized, double-blind, vehicle-controlled, phase 3 PSOARING 1 and PSOARING 2 trials, once-daily tapinarof cream 1% was shown to be efficacious in reducing the severity of plaque psoriasis. Furthermore, evidence from an open-label extension study shows that continuous and intermittent use of tapinarof cream 1% for up to 1 year has durable on-treatment efficacy with a substantial remittive effect off treatment. Tapinarof cream 1% was generally well tolerated, with few patients discontinuing treatment in the pivotal trials due to adverse events, and with no new safety signals identified with longer-term treatment. Post-marketing real-world data and/or active-controlled studies to compare tapinarof cream 1% with other topical treatments used for plaque psoriasis would be of interest. </p> <p>  </p> <p><strong>©</strong> Springer Nature Switzerland AG 2023</p>